Clinical Trial VICCTHN1244

Title

Phase 1, First-in-Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of X-396 in Patients with Advanced Solid Tumors

Principal Investigator(s)

Leora Horn

Details

  • Protocol No. VICCTHN1244
  • Open Date: 07/25/2012
  • Staging: Phase I
  • Age Group: Adults
  • Scope: National
  • Objective: To evaluate the safety/tolerability of X-396 and determine the maximum tolerated dose (MTD) of X-396 as a single agent.
  • Disease Sites: Phase I
  • Therapies: Molecular Targeted Agents / Immunotherapy / Biologics
  • Drugs: X-396
  • Participating Institutions: Vanderbilt University
  • National Clinical Trial ID: NCT01625234
  • Secondary Protocol No: X396-CLI-101

Description

Eligibility

Learn More

You do not have JavaScript enabled. This site works better with JavaScript turned on.